How well have practices followed guidelines in prescribing antihypertensive drugs: The role of health insurance

Value in Health

Volumn 6, Issue 1, 2003, Pages 18-28

  Guo, Jennifer D ^a   Liu, Gordon G ^a   Christensen, Dale B ^a   Fu, Alex Z ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antihypertensives; Guidelines; Hypertension; Insurance

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG CHOICE; ESSENTIAL HYPERTENSION; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH STATUS; HUMAN; MALE; MARRIAGE; MEDICAL FEE; MONOTHERAPY; NEGRO; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; RETROSPECTIVE STUDY;

EID: 0037283609     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2003.00212.x     Document Type: Article

References (40)

1. Brown MJ, Haydock S. Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000;59 Suppl 2:S1-12.
2. Pardell H, Tresserras R, Armario P, Hernandez del Rey R. Pharmacoeconomic considerations in the management of hypertension. Drugs 2000;59 Suppl 2:S13-20.
3. Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
5. Kaplan NM, Lieberman E. Clinical Hypertension. 7th ed. Baltimore: Williams & Wilkins; 1998.
6. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute, National High Blood Pressure Program; 1977.
7. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980;140:1280-5.
8. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984;144:1045-57.
9. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148:1023-38.
10. The fifth report of the Joint National Committee on Detection Evaluation, Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
11. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hyper tension in the Elderly Program (SHEP). SHEP, Cooperative Research Group. JAMA 1991;265:3255-64.
12. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
13. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
14. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
15. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45.
16. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998;316:838-42.
17. Moser M. Current recommendations for the treatment of hypertension: are they still valid? J Hypertens 2002;20 Suppl 1:S3-10.
18. Pearce KA, Furberg CD, Psaty BM, et al. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 1998;11:618-29.
19. Edelson JT, Weinstein MC, Tosteson AN, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:407-13.
20. Ray WA, Schaffner W, Oates JA. Therapeutic choice in the treatment of hypertension: initial treatment of newly diagnosed hypertension and secular trends in the prescribing of antihypertensive medications for Medicaid patients. Am J Med 1986;81:9-16.
21. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997;278:1745-8.
22. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
23. Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med 1988;148:788-94.
24. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64.
25. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999;21:961-72.
26. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992: an effect of the major clinical trials on clinical practice? JAMA 1995;273:1436-8.
27. Wallenius S, Peura S, Klaukka T, et al. Who is using antihypertensive drugs? A prescription analysis from Finland. Scand J Prim Health Care 1996;14:54-61.
28. Klungel OH, de Boer A, Paes AH, et al. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens 1997;15:591-600.
29. Knight EL, Glynn RJ, Levin R, et al. Failure of evidence-based medicine in the treatment of hypertension in older patients. J Gen Intern Med 2000;15:702-9.
30. Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare enrollees: does type of drug coverage matter? Health Affairs 2001;20:276-86.
31. Ahluwalia JS, McNagny SE, Rask KJ. Correlates of controlled hypertension in indigent, inner-city hypertensive patients. J Gen Intern Med 1997;12:7-14.
32. Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Affairs 2000;19:219-30.
33. Jackson MG, Drechsler-Martell CR, Jackson EA. Family practice residents' prescribing patterns. Drug Intell Clin Pharm 1985;19:205-9.
34. Gulledge J, Beard S, Health and Administration Development Group. Hypertension Management: Clinical Pathways, Guidelines, and Patient Education. Aspen Chronic Disease Management Series. Gaithersburg: Aspen; 1999.
35. Facts and Comparisons, editor. Drug Facts and Comparisons. St. Louis: Facts and Comparisons Inc.; 2000.
36. Clinical Pharmacology 2000 [Internet]. Tampa (FL): Gold Standard Multimedia; c1994-2002. Available from: http://cp.gsm.com.
37. Medical Economics Co. Drug Topics Red Book. Montvale: Medical Economics Co. Inc.; 2000.
38. Andersen RM, McCutcheon A, Aday LA, et al. Exploring dimensions of access to medical care. Health Serv Res 1983;18:49-74.
39. Jerome M, Xakellis GC, Angstman G, Patchin W. Initial medication selection for treatment of hypertension in an open-panel HMO. J Am Board Fam Pract 1995;8:1-6.
40. Shepherd MD, Salzman RD. The formulary decision-making process in a health maintenance organisation setting. Pharmacoeconomics 1994;5:29-38.